Seneca Growth Capital VCT PLC (HYG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Seneca Growth Capital VCT PLC (HYG) has a cash flow conversion efficiency ratio of -0.005x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-70.00K ≈ $-8.52 USD) by net assets (GBX13.94 Million ≈ $1.70K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Seneca Growth Capital VCT PLC - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Seneca Growth Capital VCT PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Seneca Growth Capital VCT PLC (HYG) total liabilities for a breakdown of total debt and financial obligations.
Seneca Growth Capital VCT PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Seneca Growth Capital VCT PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Solartron Public Company Limited
F:TUUF
|
0.037x |
|
Ordinary Fully Paid Deferred Settlement
AU:CNJDG
|
-0.239x |
|
Kardan NV
TA:KRNV
|
-0.001x |
|
European Resources Limited
AU:ERE
|
N/A |
|
Innoviz Technologies Ltd
NASDAQ:INVZW
|
-0.153x |
|
Nuvve Holding Corp
NASDAQ:NVVEW
|
2.691x |
|
Jack Nathan Medical Corp
V:JNH
|
0.214x |
|
WM Technology Inc
NASDAQ:MAPSW
|
0.047x |
Annual Cash Flow Conversion Efficiency for Seneca Growth Capital VCT PLC (2002–2024)
The table below shows the annual cash flow conversion efficiency of Seneca Growth Capital VCT PLC from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see Seneca Growth Capital VCT PLC stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX13.94 Million ≈ $1.70K |
GBX-257.00K ≈ $-31.27 |
-0.018x | +32.14% |
| 2023-12-31 | GBX16.89 Million ≈ $2.06K |
GBX-459.00K ≈ $-55.85 |
-0.027x | -2.42% |
| 2022-12-31 | GBX18.13 Million ≈ $2.21K |
GBX-481.00K ≈ $-58.52 |
-0.027x | -63.63% |
| 2021-12-31 | GBX17.76 Million ≈ $2.16K |
GBX-288.00K ≈ $-35.04 |
-0.016x | +9.99% |
| 2020-12-31 | GBX10.77 Million ≈ $1.31K |
GBX-194.00K ≈ $-23.60 |
-0.018x | -9.44% |
| 2019-12-31 | GBX8.38 Million ≈ $1.02K |
GBX-138.00K ≈ $-16.79 |
-0.016x | -44.12% |
| 2018-12-31 | GBX9.28 Million ≈ $1.13K |
GBX-106.00K ≈ $-12.90 |
-0.011x | +45.72% |
| 2017-12-31 | GBX5.18 Million ≈ $630.26 |
GBX-109.00K ≈ $-13.26 |
-0.021x | +11.57% |
| 2016-12-31 | GBX5.55 Million ≈ $674.91 |
GBX-132.00K ≈ $-16.06 |
-0.024x | +4.05% |
| 2015-12-31 | GBX6.13 Million ≈ $745.72 |
GBX-152.00K ≈ $-18.49 |
-0.025x | -133.18% |
| 2014-12-31 | GBX7.33 Million ≈ $892.34 |
GBX-78.00K ≈ $-9.49 |
-0.011x | +59.38% |
| 2013-12-31 | GBX7.83 Million ≈ $952.56 |
GBX-205.00K ≈ $-24.94 |
-0.026x | -60.01% |
| 2012-12-31 | GBX9.59 Million ≈ $1.17K |
GBX-157.00K ≈ $-19.10 |
-0.016x | -141.15% |
| 2011-12-31 | GBX5.73 Million ≈ $697.54 |
GBX228.00K ≈ $27.74 |
0.040x | +159.77% |
| 2010-12-31 | GBX6.28 Million ≈ $764.34 |
GBX-418.00K ≈ $-50.86 |
-0.067x | -2445.99% |
| 2009-12-31 | GBX7.40 Million ≈ $900.85 |
GBX21.00K ≈ $2.56 |
0.003x | +108.45% |
| 2008-12-31 | GBX5.16 Million ≈ $627.21 |
GBX-173.00K ≈ $-21.05 |
-0.034x | -26.76% |
| 2007-12-31 | GBX4.61 Million ≈ $560.66 |
GBX-122.00K ≈ $-14.84 |
-0.026x | +70.85% |
| 2006-12-31 | GBX4.29 Million ≈ $522.46 |
GBX-390.00K ≈ $-47.45 |
-0.091x | -142.16% |
| 2005-12-31 | GBX5.68 Million ≈ $690.97 |
GBX-213.00K ≈ $-25.92 |
-0.038x | -152.01% |
| 2004-12-31 | GBX6.29 Million ≈ $765.92 |
GBX454.00K ≈ $55.24 |
0.072x | +489.40% |
| 2003-12-31 | GBX6.91 Million ≈ $840.87 |
GBX-128.00K ≈ $-15.57 |
-0.019x | -135.08% |
| 2002-12-31 | GBX6.73 Million ≈ $818.48 |
GBX-53.00K ≈ $-6.45 |
-0.008x | -- |
About Seneca Growth Capital VCT PLC
Seneca Growth Capital VCT plc is a venture capital trust specializes in growth capital. It invests in emerging biotechnology companies. It prefers to invest in unquoted and quoted MedTech companies. The fund seeks to invest in the United Kingdom, IIe-de-France, Burgundy, France, European Developed Markets. It typically invests in companies with sales greater than £10 million ($11.90 million), gro… Read more